🧪
hypothesis

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation

Hypothesis

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation.
🧬 Microglial TREM2🩺 connectomics🎯 Composite 53%💱 $0.53▼3.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 5 support 4 oppose
⚠ Missing Evidence⚠ Thin Description Senate Quality Gates →
Mechanistic 0.70 (15%) Evidence 0.65 (15%) Novelty 0.75 (12%) Feasibility 0.50 (12%) Impact 0.65 (12%) Druggability 0.55 (10%) Safety 0.40 (8%) Competition 0.55 (6%) Data Avail. 0.65 (5%) Reproducible 0.40 (5%) KG Connect 0.50 (8%) 0.535 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite53%

🧪 Overview

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
    B["TREM2 Receptor<br/>Ligand Binding"]
    C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
    D["SYK Kinase<br/>Activation"]
    E["PLCG2<br/>IP3 + DAG Generation"]
    F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
    G["Microglial Phagocytosis<br/>Plaque Compaction"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix5 supports4 contradicts
Supports
TREM2 loss-of-function variants increase AD risk 2-4 fold
PMID:26928458
Supports
TREM2 is required for microglial response to amyloid plaques
PMID:26551527
Supports
TREM2 agonist promotes microglial clustering around plaques and reduces neurite dystrophy
PMID:31171641
Supports
Hub regions show heightened connectivity burden correlating with pathology
PMID:19219025
Supports
Synaptic loss in AD correlates with dysregulated microglial surveillance
PMID:29186337
Contradicts
AL002c (TREM2 agonist) failed to meet primary endpoint in INVOKE-2 Phase 2 trial (2024)
PMID:38427984
Contradicts
TREM2 deficiency reduces amyloid pathology in some contexts (reduced microglial clustering)
PMID:29307019
Contradicts
Microglial states in AD are heterogeneous - single pathway modulation insufficient
PMID:31249461
Contradicts
Mouse-to-human microglial translation limitations affect validity
PMID:29422609
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MICROGLIAL

No curated PDB or AlphaFold mapping for MICROGLIAL yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for Microglial TREM2 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Microglial TREM2 →

No DepMap CRISPR Chronos data found for Microglial TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0241
Events (7d)
3
Price History
▼3.4%

💾 Resource Usage

LLM Tokens
47,826
$0.1435
Total Cost
$0.1435

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we administer a selective TREM2 agonist (anti-TREM2 agonistic antibody at 10mg/kg, weekly ip) to 6-month-old 5xFAD mice for 8 weeks, THEN we will observe a significant reduction in cortical synapti≥20% reduction in excitatory synapse density (PSD-95/vGLUT1 puncta) in cortical layer 5 neurons in the agonist-treated group versus vehicle controls— no observation —pending0.65
IF we perform longitudinal in vivo two-photon microscopy to monitor dendritic spine turnover in Trem2^R47H knock-in mice crossed with Thy1-YFP reporters following a 4-week regimen of TREM2-activating Spine elimination rate increases to ≥0.05eliminations/hour with unchanged spine formation rate (<0.05/hour), yielding net spine density reduction of 15-25%— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we administer a selective TREM2 agonist (anti-TREM2 agonistic antibody at 10mg/kg, weekly ip) to 6-month-old 5xFAD mice for 8 weeks, THEN we will observe a significant reduction in cortical synaptic density (measured by PSD-95+ vGLUT1 colocalization via confocal microscopy) compared to vehicle-tr
Predicted outcome: ≥20% reduction in excitatory synapse density (PSD-95/vGLUT1 puncta) in cortical layer 5 neurons in the agonist-treated group versus vehicle controls
Falsification: No significant difference in synaptic density between TREM2 agonist and vehicle groups (p>0.05) OR paradoxical increase in synapse number, indicating impaired rather than enhanced pruning
pendingconf 58%
IF we perform longitudinal in vivo two-photon microscopy to monitor dendritic spine turnover in Trem2^R47H knock-in mice crossed with Thy1-YFP reporters following a 4-week regimen of TREM2-activating nanobodies (0.5mg/kg, biweekly), THEN we will observe increased spine elimination rate (≥30% elevati
Predicted outcome: Spine elimination rate increases to ≥0.05eliminations/hour with unchanged spine formation rate (<0.05/hour), yielding net spine density reduction of 1
Falsification: Spine elimination rate remains unchanged (<5% difference from baseline) or spine formation rate increases significantly, indicating TREM2 activation does not selectively enhance pruning
View on SciDEX ↗